Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Septaphage
- Development stage
- Unknown
- Lead developer
- Biochimpharm
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Topical, Rectal, Vaginal, Intranasal, Otic
01
Overview
Septaphage is a polyvalent bacteriophage cocktail developed by Biochimpharm for the treatment and prophylaxis of acute and chronic bacterial infections. The product contains a mixture of lytic bacteriophages that selectively target and destroy seven groups of pathogenic bacteria: *Shigella*, *Salmonella*, *Escherichia coli*, *Proteus*, *Enterococcus*, *Staphylococcus*, and *Pseudomonas aeruginosa*. The mechanism of action involves the selective infection of these pathogens, where the phages replicate within the bacterial cells and cause them to burst (lysis), while leaving the patient's natural microbiome intact. Septaphage is approved in Georgia for a variety of indications, including gastrointestinal infections (such as dysentery and salmonellosis), urogenital infections, and respiratory tract infections. It is typically administered as an oral solution, but can also be used topically or via other mucosal routes.
- Brand names
- Septaphage
- Other names
- Septaphage
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on Septaphage.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Septaphage.